Traws Pharma, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 17
- Market Cap
- -
- Website
- http://www.trawspharma.com
Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT06402136
- Locations
- ๐ฆ๐บ
Scientia Clinical Research, Sydney, Greater Sydney Area, Australia
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05705505
- Locations
- ๐บ๐ธ
NYU Langone, New York, New York, United States
๐บ๐ธTexas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
๐บ๐ธArizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
Study of ON 123300 in Patients With Advanced Cancer
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04739293
- Locations
- ๐บ๐ธ
Mary Crowley Cancer Research, Dallas, Texas, United States
๐บ๐ธGreenville Health System, Institute for Oncology Clinical Research, Greenville, South Carolina, United States
๐บ๐ธSTART Midwest, Grand Rapids, Michigan, United States
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT02562443
- Locations
- ๐บ๐ธ
New York Medical College, Valhalla, New York, United States
๐บ๐ธUSC Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธUniversity of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02168725
- Locations
- ๐บ๐ธ
University of Colorado Hospital Anschutz Medical Campus, Aurora, Colorado, United States
๐บ๐ธRoswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธSarah Cannon Research Institute, Nashville, Tennessee, United States
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02107235
- Locations
- ๐บ๐ธ
University of Colorado Cancer Center, Aurora, Colorado, United States
๐บ๐ธThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
๐บ๐ธChristiana Care Health Services, Newark, Delaware, United States
Three Dosing Schedules of Oral Rigosertib in MDS Patients
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Traws Pharma, Inc.
- Registration Number
- NCT02075034
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02030639
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
- Conditions
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01928537
- Locations
- ๐บ๐ธ
Stanford University Cancer Center, Stanford, California, United States
๐บ๐ธMount Sinai Medical Center, New York, New York, United States
๐บ๐ธMayo Clinic, Rochester, Minnesota, United States
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
- Conditions
- Interventions
- First Posted Date
- 2013-08-21
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Traws Pharma, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT01926587
- Locations
- ๐บ๐ธ
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธMount Sinai Medical Center, New York, New York, United States